Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer

Lung Cancer

Volumn 46, Issue 2, 2004, Pages 255-261

  Hotta, Katsuyuki ^a   Kiura, Katsuyuki ^b   Ueoka, Hiroshi ^a   Tabata, Masahiro ^b   Fujiwara, Keiichi ^b   Kozuki, Toshiyuki ^a   Okada, Toshiaki ^a   Hisamoto, Akiko ^a   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Brain metastasis; Extracranial disease; Gefitinib; Non small cell lung cancer; Prior chemotherapy; Skin reaction

Indexed keywords

GEFITINIB;

ADRENAL DISEASE; ADULT; ADVANCED CANCER; AGED; BONE DISEASE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRUG SENSITIVITY; DRUG TOLERABILITY; EXPERIENCE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; LIVER DISEASE; LIVER TOXICITY; LUNG DISEASE; LUNG NON SMALL CELL CANCER; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; NAUSEA; OBSERVATION; PLEURA DISEASE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; REVIEW; SKIN DISEASE; SKIN MANIFESTATION; UNIVERSITY HOSPITAL; VOMITING;

EID: 4944226682     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.04.036     Document Type: Article

References (18)

1. Stanley K., Stjernsward J. Lung cancer - a worldwide health problem. Chest. 96(Suppl 1):1989;1S-5S
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311: 899-909.
3. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl. J. Med. 346:2002;92-98
4. Rusch V., Baselga J., Cordon-Cardo C., Orazem J., Zaman M., Hoda S., et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 53:1993;2379-2385
5. Volm M., Rittgen W., Drings P. Prognostic value of ERBB-1, VEGF, cyclin A., FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br. J. Cancer. 77:1998;663-669
6. Lawrence D.S., Niu J. Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacol. Ther. 77:1998;81-114
7. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21:2003;2237-2246
8. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J. Jr., Prager D., Belani C.P., Schiller J.H., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA. 290:2003;2149-2158
9. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer. Inst. 92:2000;205-216
10. Shimoyama M. The Japanese edition of the National Cancer Institute Common Toxicity Criteria. Gan to Kagaku Ryoho. 26:1999;1084-1144. [Japanese]
11. Fujiwara K., Kiura K., Ueoka H., Tabata M., Hamasaki S., Tanimoto M. Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer. 40:2003;73-76
12. Cappuzzo F., Ardizzoni A., Soto-Parra H., Gridelli C., Maione P., Tiseo M., Calandri C., et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer. 41:2003;227-231
13. Heimberger A.B., Learn C.A., Archer G.E., McLendon R.E., Chewning T.A., Tuck F.L., et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 8:2002;3496-3502
14. AstraZeneca data on file.
15. Hortobagyi G.N. Developments in chemotherapy of breast cancer. Cancer. 88(Suppl 12):2000;3073-3079
16. Manley P.W., Cowan-Jacob S.W., Buchdunger E., Fabbro D., Fendrich G., Furet P., et al. Imatinib: a selective tyrosine kinase inhibitor. Eur. J. Cancer. 38(Suppl 5):2002;S19-27
17. Shah N.T., Miller V.A., Kris M.G., Patel J., Venkatraman E., Benporat L., et al. Bronchioalveolar histology and smoking history predict response to gefitinib. Proc. Am. Soc. Clin. Oncol. 22:2003;628. [abstract 2524]
18. Gridelli C., Maione P., Castaldo V., Rossi A. Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br. J. Cancer. 89:2003;1827-1829